Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365532 · ClinicalTrials.gov registry record · Phase 1
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
A Phase 1 study of Long QT Syndrome, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02365532 is a Phase 1 study of Long QT Syndrome that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants, below the 673-participant average among 7 other Long QT Syndrome trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02365532, a Phase 1 study of Long QT Syndrome, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
Conditions Studied
Interventions
- DRUG GS-6615
- DRUG Placebo to match GS-6615
- DRUG Placebo to match dofetilide
- DRUG Dofetilide
Study Locations (1)
Wisconsin
- Spaulding Clinical Research, LLC - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365532
The ClinicalTrials.gov registry entry for NCT02365532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 673-participant average among 7 other Long QT Syndrome trials with a reported enrollment target (91% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long QT Syndrome appearing as the primary indexed condition, and to 4 interventions - of which GS-6615 is the first listed.
NCT02365532 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02365532 about?
NCT02365532 is a clinical study titled "Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults". This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
What is the current status of trial NCT02365532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-02. Estimated completion is 2015-05.
What conditions does trial NCT02365532 study?
This clinical trial studies the following conditions: Long QT Syndrome.
What interventions are being tested in trial NCT02365532?
The interventions under investigation include: GS-6615 (DRUG), Placebo to match GS-6615 (DRUG), Placebo to match dofetilide (DRUG), Dofetilide (DRUG).
Who is sponsoring clinical trial NCT02365532?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365532 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long QT Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Continuous Versus Intermittent cARdiac Electrical moNitorinG
RECRUITING · NA
-
Exercise in Genetic Cardiovascular Conditions
COMPLETED
-
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
COMPLETED · Phase 4
-
Long QT Syndrome and Sleep Apnea
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.